Shields Matthew bought TEVA
June 3, 2024 · Form 4 insider transaction
Shields Matthew bought 64,782 shares of Teva Pharmaceutical Industries Limited at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.; Restricted share units were granted on June 3, 2024, with 16,195 vesting on each of June 3, 2025, June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028.; The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.